# Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

> **NCT05174832** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 136 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Pembrolizumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05174832
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-07
- **Primary completion:** 2023-12-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174832, "Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05174832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*